---
title: "Aurobindo Pharma Ltd (AUROPHARMA) — Share Price, Financials & Analysis"
symbol: "AUROPHARMA"
company: "Aurobindo Pharma Ltd"
canonical: "https://tapetide.com/stocks/AUROPHARMA"
isin: "INE406A01037"
nse_symbol: "AUROPHARMA"
bse_code: "524804"
sector: "Healthcare"
industry: "Pharmaceuticals"
market_cap_cr: 95535.75
generated_at: "2026-09-13T19:08:13.703Z"
---

# Aurobindo Pharma Ltd (AUROPHARMA)

Canonical page: https://tapetide.com/stocks/AUROPHARMA

## Company

- **NSE Symbol:** AUROPHARMA
- **BSE Code:** 524804
- **ISIN:** INE406A01037
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 1995-04-06
- **CEO:** Mr. Kambam Nithyananda Reddy
- **Employees:** 27707
- **Face Value:** ₹1
- **F&O Eligible:** Yes
- **Website:** aurobindo.com

## About

Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.(Source : 202003 Annual Report Page No:159)

## Latest Price

- **Price:** ₹1679.8
- **Change:** +11.4 (+0.68%)
- **Open:** ₹1666.7
- **Day High:** ₹1681.4
- **Day Low:** ₹1655.5
- **Previous Close:** ₹1668.4
- **Volume:** 494251
- **As Of:** 2026-09-11T10:26:04+00:00

## Key Fundamentals

Observed at 2026-09-11T04:33:44.174652Z.

- **Market Cap:** ₹95535.75 Cr
- **Classification:** Midcap
- **P/E (reported):** 25.9
- **P/E (TTM):** 26.21
- **EPS (TTM):** ₹64.09
- **EPS (reported):** ₹61.22
- **Book Value:** ₹658.53
- **Price to Book:** 2.53
- **Dividend Yield:** 0.24%
- **ROE:** 9.25%
- **ROCE:** 13.58%
- **Debt to Equity:** 0.21
- **Revenue (yearly):** ₹34145.2 Cr
- **Net Income:** ₹3503 Cr
- **EBITDA:** ₹7337.8 Cr
- **52-Week High:** ₹1717
- **52-Week Low:** ₹1048
- **RSI (14):** 55.21

## Tapetide Score

- **Score:** 58 / 100
- **Score date:** 2026-09-04
- **Archetype:** Cheap but Weak
- **What it means:** A low multiple sitting on weak financials. Worth establishing what the market is discounting before treating the low valuation as an opportunity — weak fundamentals often justify it.
- **Pillar profile:** Quality: Weak · Valuation: Cheap · Momentum: Rising
- **Percentile:** 81.3 (of 4473 scored stocks)
- **Confidence:** 100%
- **Data coverage:** 100%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 48.94 | 9% |
| growth | 21.03 | 9% |
| momentum | 61.07 | 12% |
| ownership | 68.24 | 24% |
| quality | 41.33 | 22% |
| valuation | 78.94 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Weaknesses

- Stock is trading at 2.57 times its book value
- The company has delivered a poor sales growth of 6.32% over past five years.
- Company has a low return on equity of 10.8% over last 3 years.
- Company might be capitalizing the interest cost

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | 40.81% | 127% | 10.16% |
| ebitda margin growth | 16.62% | -3.5% | -0.74% | 8.54% |
| net income growth | 12.08% | 0.56% | 23% | 1% |
| revenue growth | 5.66% | 5.56% | 11% | 6% |
| roce | 16.41% | -13.72% | -4.43% | 13.3% |
| roe | 12.07% | -13.31% | 10.18% | -14.11% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 7219 | 7352 | 7580 | 7567 | 7796 | 7979 | 8382 | 7868 | 8286 | 8646 | 8853 | 9150 |
| Expenses | 5846 | 5753 | 5920 | 5949 | 6230 | 6401 | 6622 | 6265 | 6608 | 6873 | 7103 | 7271 |
| Operating Profit | 1373 | 1599 | 1660 | 1618 | 1566 | 1578 | 1760 | 1603 | 1678 | 1773 | 1750 | 1880 |
| OPM % | 19 | 22 | 22 | 21 | 20 | 20 | 21 | 20 | 20 | 21 | 20 | 21 |
| Other Income | 188 | 163 | 14 | 221 | 136 | 159 | 135 | 107 | 122 | 123 | 117 | 224 |
| Interest | 68 | 76 | 89 | 111 | 113 | 118 | 115 | 98 | 95 | 93 | 98 | 102 |
| Depreciation | 418 | 423 | 354 | 404 | 382 | 419 | 444 | 406 | 429 | 465 | 479 | 487 |
| Profit before tax | 1076 | 1262 | 1230 | 1324 | 1207 | 1200 | 1335 | 1207 | 1276 | 1339 | 1291 | 1515 |
| Tax % | 30 | 26 | 26 | 31 | 32 | 30 | 32 | 32 | 34 | 32 | 29 | 32 |
| Net Profit | 752 | 940 | 907 | 918 | 817 | 846 | 903 | 824 | 848 | 910 | 921 | 1032 |
| EPS in Rs | 12.92 | 15.98 | 15.51 | 15.69 | 14.07 | 14.56 | 15.56 | 14.2 | 14.61 | 15.67 | 15.86 | 17.95 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 16463 | 19564 | 23099 | 24775 | 23455 | 24855 | 29002 | 31724 | 33653 | 34935 |
| Expenses | 12691 | 15612 | 18249 | 19497 | 19060 | 21148 | 23176 | 25164 | 26783 | 27854 |
| Operating Profit | 3772 | 3952 | 4849 | 5278 | 4396 | 3707 | 5826 | 6560 | 6870 | 7081 |
| OPM % | 23 | 20 | 21 | 21 | 19 | 15 | 20 | 21 | 20 | 20 |
| Other Income | 105 | 70 | 166 | 3195 | 152 | 291 | 366 | 613 | 404 | 586 |
| Interest | 78 | 263 | 305 | 74 | 49 | 140 | 290 | 457 | 384 | 388 |
| Depreciation | 558 | 668 | 967 | 1055 | 1127 | 1245 | 1522 | 1649 | 1778 | 1859 |
| Profit before tax | 3241 | 3091 | 3743 | 7344 | 3373 | 2612 | 4380 | 5066 | 5112 | 5420 |
| Tax % | 25 | 24 | 24 | 27 | 22 | 26 | 28 | 31 | 31 | — |
| Net Profit | 2423 | 2364 | 2844 | 5334 | 2647 | 1928 | 3169 | 3484 | 3503 | 3711 |
| EPS in Rs | 41.36 | 40.36 | 48.56 | 91.05 | 45.2 | 32.9 | 54.15 | 60.02 | 60.34 | 64.09 |
| Dividend Payout % | 6 | 6 | 6 | 4 | 20 | 23 | 8 | 0 | 7 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 59 | 59 | 59 | 59 | 59 | 59 | 59 | 59 | 58 | 58 |
| Reserves | 9313 | 11622 | 13832 | 16766 | 21871 | 24517 | 26781 | 29784 | 32595 | 37833 |
| Borrowings | 3364 | 4770 | 6967 | 5826 | 5339 | 2851 | 5286 | 6648 | 8263 | 8073 |
| Other Liabilities | 3464 | 4492 | 5414 | 6113 | 6147 | 6211 | 7379 | 8227 | 8566 | 12232 |
| Total Liabilities | 16200 | 20942 | 26271 | 28765 | 33416 | 33638 | 39505 | 44717 | 49482 | 58196 |
| Fixed Assets | 4834 | 6521 | 8475 | 9396 | 9374 | 10532 | 11024 | 14493 | 14794 | 17407 |
| CWIP | 1458 | 1583 | 1668 | 1986 | 3062 | 3747 | 5390 | 3869 | 4900 | 5214 |
| Investments | 246 | 312 | 360 | 555 | 591 | 997 | 543 | 372 | 252 | 1051 |
| Other Assets | 9662 | 12527 | 15768 | 16827 | 20390 | 18362 | 22549 | 25983 | 29536 | 34525 |
| Total Assets | 16200 | 20942 | 26271 | 28765 | 33416 | 33638 | 39505 | 44717 | 49482 | 58196 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 3279 | 1955 | 1651 | 4381 | 3329 | 5016 | 2387 | 2435 | 3925 | 5526 |
| Cash from Investing Activity | -1787 | -1927 | -2904 | -1563 | 597 | -3211 | -3971 | -4242 | -1866 | -2630 |
| Cash from Financing Activity | -1915 | 864 | 1919 | -1947 | -1365 | -2969 | 1814 | 800 | 120 | -1269 |
| Net Cash Flow | -424 | 892 | 666 | 871 | 2561 | -1164 | 230 | -1007 | 2178 | 1628 |
| Free Cash Flow | 1594 | 714 | 114 | 2969 | 1503 | 2693 | -323 | -1067 | 1408 | 2468 |
| CFO/OP | 118 | 70 | 61 | 106 | 87 | 143 | 84 | 72 | 86 | 107 |

### Ratios

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 68 | 68 | 64 | 68 | 52 | 62 | 66 | 61 | 66 | 77 |
| Inventory Days | 246 | 317 | 304 | 289 | 333 | 272 | 275 | 284 | 295 | 326 |
| Days Payable | 122 | 128 | 107 | 97 | 103 | 97 | 125 | 129 | 117 | 151 |
| Cash Conversion Cycle | 191 | 257 | 260 | 260 | 282 | 237 | 216 | 216 | 244 | 252 |
| Working Capital Days | 51 | 50 | 25 | 35 | 52 | 84 | 55 | 66 | 49 | 44 |
| ROCE % | 25 | 23 | 18 | 19 | 18 | 13 | 9 | 14 | 14 | 13 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 51.83% | 51.83% | 51.83% | 51.8% | 51.82% | 51.82% | 51.82% | 51.82% | 51.82% | 51.82% | 51.82% | 51.88% |
| FIIs | 22.45% | 20.72% | 18.02% | 16.73% | 16.59% | 16.29% | 15.33% | 14.37% | 14.21% | 13.94% | 15.24% | 16.38% |
| DIIs | 17.94% | 20.23% | 23.28% | 24.77% | 25.13% | 25.2% | 26.23% | 26.93% | 27.6% | 27.68% | 25.87% | 25.1% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 6.15% | 5.64% | 5.52% | 5.47% | 5.33% | 5.52% | 5.47% | 5.67% | 5.25% | 5.36% | 5.74% | 5.36% |
| Others | 1.62% | 1.57% | 1.36% | 1.23% | 1.13% | 1.17% | 1.15% | 1.2% | 1.13% | 1.19% | 1.34% | 1.28% |
| No. of Shareholders | 259638 | 241944 | 244575 | 238622 | 248488 | 257962 | 269323 | 272208 | 247662 | 236859 | 241298 | 239073 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Buy
- **Buy / Neutral / Sell:** 13 / 6 / 0

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 1673.8 | Buy |
| EMA (10) | 1668.82 | Buy |
| SMA (20) | 1649.76 | Buy |
| EMA (20) | 1653.63 | Buy |
| SMA (50) | 1609 | Buy |
| EMA (50) | 1608.96 | Buy |
| SMA (100) | 1540.76 | Buy |
| EMA (100) | 1536.51 | Buy |
| SMA (200) | 1383.08 | Buy |
| EMA (200) | 1429.33 | Buy |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 57.04 | Neutral |
| MACD (12,26,9) | 21.03 | Buy |
| Stochastic (14,3,3) | 70.7 | Neutral |
| ADX (14) | 25.6 | Buy |
| Williams %R (14) | -31.47 | Neutral |
| ATR (14) | 37.77 | Neutral |
| ROC (12) | 3.5 | Buy |
| Stoch RSI (14) | 28.74 | Neutral |
| UO (7,14,28) | 62.43 | Neutral |

## Analyst Ratings

| Recommendation | Analysts | Share |
| --- | --- | --- |
| Buy | 17 | 62.96% |
| Hold | 5 | 18.52% |
| Sell | 5 | 18.52% |

Based on 27 analyst ratings, observed at 2026-09-11T04:33:44.191358+00:00.

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 9h - Aurobindo to complete up to 26% acquisition in Swarnaakshu by June 30, 2026 (delayed from March 31). | [Update On Solar Power Purchase Agreement And Acquisition Upto 26% Stake In Swarnaakshu Solar Power Private Limited. 9h - Aurobindo to complete up to 26% acquisition in Swarnaakshu by June 30, 2026 (delayed from March 31).](https://www.bseindia.com/xml-data/corpfiling/AttachLive/9b255c36-388a-46c0-961c-20d9e75492ad.pdf) |
| 9 Mar - Of investor meet to be held on 13.03.2026. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 9 Mar - Of investor meet to be held on 13.03.2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/0e29da44-919d-403e-ae2c-807923749245.pdf) |
| 9 Apr - Regulation 74(5) certificate filed for quarter ended March 31, 2026. | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 9 Apr - Regulation 74(5) certificate filed for quarter ended March 31, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/45934fa7-23f0-45f5-9bb5-e380eeffc829.pdf) |
| 8h - Aurobindo Pharma gets USFDA approval for Dapagliflozin 5 mg, 10 mg; launch begins immediately. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 8h - Aurobindo Pharma gets USFDA approval for Dapagliflozin 5 mg, 10 mg; launch begins immediately.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/b52b9640-1a5f-4412-91ee-f2b0ebff5769.pdf) |
| 8 May - Submission of copy of post buyback public advertisement pertaining to buyback of shares of the Company. | [Announcement under Regulation 30 (LODR)-Newspaper Publication 8 May - Submission of copy of post buyback public advertisement pertaining to buyback of shares of the Company.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/6038669d-47c7-4b93-bc86-882f98dbb88d.pdf) |
| 8 Apr - Submission of Public Announcement pertaining to Buyback of shares of the Company published in newspapers and Board Resolution. | [Announcement under Regulation 30 (LODR)-Newspaper Publication 8 Apr - Submission of Public Announcement pertaining to Buyback of shares of the Company published in newspapers and Board Resolution.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/a62dbd27-13af-4e9f-b2ac-6522db337044.pdf) |
| 8 Apr - Submission of Public Announcement pertaining to Buyback of shares of the Company published in newspapers | [Announcement under Regulation 30 (LODR)-Newspaper Publication 8 Apr - Submission of Public Announcement pertaining to Buyback of shares of the Company published in newspapers](https://www.bseindia.com/xml-data/corpfiling/AttachHis/298e5102-d88c-4a30-8938-4f2dc3886c23.pdf) |
| 7 Apr - Aurobindo Pharma received USFDA approval for Dapagliflozin/Metformin ER tablets and will launch immediately. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 7 Apr - Aurobindo Pharma received USFDA approval for Dapagliflozin/Metformin ER tablets and will launch immediately.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/ca6a7a08-3430-4159-bf1d-857abf13227e.pdf) |
| 6h - Board meeting on April 6, 2026 to consider buyback of fully paid-up equity shares. | [Board Meeting Intimation for To Consider, Inter Alia, A Proposal For Buyback Of The Fully Paid-Up Equity Shares Of The Company 6h - Board meeting on April 6, 2026 to consider buyback of fully paid-up equity shares.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/99e419b6-697b-4386-b5b3-27ffd114eaf2.pdf) |
| 6 May - US FDA closed Unit-VII inspection; facility classified VAI after Jan 28-Feb 10, 2026 inspection. | [US FDA Classification Of Unit-VII Of Aurobindo Pharma Limited, As Voluntary Action Indicated (VAI) 6 May - US FDA closed Unit-VII inspection; facility classified VAI after Jan 28-Feb 10, 2026 inspection.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/25046736-dd9f-433f-994c-0cee10731ba6.pdf) |

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-03 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e7469acc-cc95-47e5-9f6f-84394be407ac.pdf) |
| 2026-09-01 | [Announcement under Regulation 30 (LODR)-Acquisition](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e5ff606e-edf5-45c9-9590-8a3d84bde706.pdf) |
| 2026-08-31 | [Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c564ad63-5765-4226-966f-2a26a9dffb90.pdf) |
| 2026-08-28 | [Shareholder Meeting / Postal Ballot-Scrutinizers Report](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a1855fe8-385d-45f3-9c07-08c34c77f9b0.pdf) |
| 2026-08-28 | [Completion Of US FDA Inspection At Unit-VI Of Apitoria Pharma Private Limited A Wholly Owned Subsidiary Of The Company](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=12f42de4-c177-49ff-934e-55401654b4f7.pdf) |
| 2026-08-27 | [Shareholder Meeting / Postal Ballot-Outcome of AGM](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1e16491a-57a2-44fd-9caa-bb1da0962f2c.pdf) |
| 2026-08-25 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0cace350-c467-4dc4-88c4-0333ba05a07c.pdf) |
| 2026-08-25 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c7dfcc06-4e8e-4fd8-a40f-7edc4a8eb63a.pdf) |
| 2026-08-24 | [Completion Of US FDA Inspection At Lannett Company LLC A Wholly Owned Subsidiary Of Aurobindo Pharma USA Inc.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b72c376c-cb98-4058-8e2b-a721fcb304f1.pdf) |
| 2026-08-21 | [Completion Of US FDA Inspection At Auro Peptides Ltd A Subsidiary/Business Arm Of The Company.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=22b0319d-27dd-4673-85fd-454bd91f4977.pdf) |

### Earnings Call Transcripts

| Date | Document |
| --- | --- |
| 2026-08-13 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=649d2e0e-7f23-4dce-8d2c-623d34bce215.pdf) |
| 2026-05-27 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=02f5135a-64d6-4a73-ab79-22338c70b732.pdf) |
| 2026-02-16 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=32148f1f-47ad-42f0-a8e7-8a15130df027.pdf) |
| 2025-11-11 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=38fa1702-0014-46be-805a-43fd18f17cc1.pdf) |
| 2025-08-08 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cba3da3b-6c58-4ea1-99f1-5853086d9a8a.pdf) |
| 2025-06-02 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=18df2504-0212-4327-971e-954b70abb3bf.pdf) |
| 2025-02-13 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7a1fdc43-c10e-460c-a60f-512ed9cd4218.pdf) |

### Investor Presentations

| Date | Document |
| --- | --- |
| 2026-08-05 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=01076371-b3b6-4225-ab1c-485173891041.pdf) |
| 2026-05-21 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d6c492da-ca2e-4a8c-bcea-6c7110e748fa.pdf) |
| 2026-02-10 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=04527598-c3a8-4c8c-a952-b486638c9178.pdf) |
| 2026-02-09 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ca5c35e2-908b-4fbc-94d1-07553c6f2594.pdf) |
| 2025-11-05 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f3f251a0-a55f-47f8-88cf-8e712f9ff554.pdf) |
| 2025-08-04 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8315ee0f-ddb9-4da4-808f-ca32938618e5.pdf) |
| 2025-05-26 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=052022b5-95e0-45ba-bf01-6c1db76b5d9f.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-05-21 | [Financial Results For The Year Ended March 31 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5309a27e-4b61-4d6d-8c5c-d23e846a9c21.pdf) |
| 2026-02-09 | [Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d3d9a63a-1119-42ea-a844-2814388d6a99.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/38fa1702-0014-46be-805a-43fd18f17cc1.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/02f5135a-64d6-4a73-ab79-22338c70b732.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachLive/02f5135a-64d6-4a73-ab79-22338c70b732.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d6c492da-ca2e-4a8c-bcea-6c7110e748fa.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachLive/d6c492da-ca2e-4a8c-bcea-6c7110e748fa.pdf) |
| Jun 2025 | [Concall - Jun 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/18df2504-0212-4327-971e-954b70abb3bf.pdf) |
| Feb 2026 | [Concall - Feb 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/ca5c35e2-908b-4fbc-94d1-07553c6f2594.pdf) |
| Feb 2026 | [Concall - Feb 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/32148f1f-47ad-42f0-a8e7-8a15130df027.pdf) |
| Aug 2025 | [Concall - Aug 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/cba3da3b-6c58-4ea1-99f1-5853086d9a8a.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Annual Report 2026 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/ec25ad91-8862-484e-b848-03b3d5e520c9.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:08:13.703Z.